Anderson C F
Division of Nephrology, Mayo Clinic, Rochester, MN 55905.
Mayo Clin Proc. 1993 Apr;68(4):358-62. doi: 10.1016/s0025-6196(12)60131-1.
Hyperlipoproteinemia is common in patients with renal disease, but increased lipids are only one of several risk factors frequently identified for coronary artery disease. Before treatment options are instituted, renal disease status, current medications, and possible interactions between drugs must be considered. Hypertriglyceridemia is common in patients with renal failure; therapeutic options are influenced by the levels of serum triglycerides and high-density lipoprotein cholesterol. If nonsteroidal drugs improve renal function and decrease proteinuria in patients with renal disease, hyperlipidemia frequently abates. Interactions between drugs are important considerations when lipid-lowering drug treatment is prescribed in recipients of renal transplants.
高脂蛋白血症在肾病患者中很常见,但血脂升高只是冠状动脉疾病常见的多种危险因素之一。在制定治疗方案之前,必须考虑肾病状态、当前用药情况以及药物之间可能的相互作用。高甘油三酯血症在肾衰竭患者中很常见;治疗方案受血清甘油三酯和高密度脂蛋白胆固醇水平的影响。如果非甾体类药物能改善肾病患者的肾功能并减少蛋白尿,高脂血症通常会减轻。在为肾移植受者开降脂药物治疗时,药物相互作用是重要的考虑因素。